In someone with an asymptomatic JAK2 V617 mutated and BCR/ABL negative MPN with a steadily rising WBC, when do you decide to start cytoreductive therapy and which agent(s) do you recommend?
No evidence of palpable splenomegaly, normal hematocrit and platelet count
Community PollStarted
What do you use to treat an asymptomatic patient with progressive leukocytosis and a JAK2 V617 driver mutation?
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Hematology · Johns Hopkins University
Answered on
First, let's abandon the phase "BCR/ABL-negative MPN". This is an oxymoron because BCR/ABL can be expressed in a JAK2 driver mutation-positive MPN. In fact, both BCR/ABL and JAK2 mutations can be expressed in normal individuals at very low levels without causing disease. Both mutations can also be p...
Join for free or sign in to see the full answer